Advertisement

Drugs

, Volume 41, Supplement 1, pp 18–24 | Cite as

Cilazapril

A Review
  • Thomas Szucs
Article

Summary

Cilazapril is a new nonthiol group containing angiotensin converting enzyme (AGE) inhibitor, which was designed by a computer-modelling technique in order to obtain a compound with high specificity and selectivity for the target enzyme.

Cilazapril has been investigated in more than 4000 patients with all degrees of hypertension, as well as in special patient groups such as the elderly, renally impaired, and patients with concomitant diseases, such as congestive cardiac failure or chronic obstructive pulmonary disease. In these studies, the blood pressure-lowering effect of a single daily dose has been clearly established. The tolerability profile is similar to other frequently prescribed antihypertensive drugs, such as sustained-release propranolol, enalapril, captopril, atenolol and hydrochlorothiazide. Recently, investigations have revealed that cilazapril, in addition to its blood pressure-lowering abilities, can moderate the proliferative response seen in vessels after vascular injury caused by techniques such as ballooning. Clinical studies to verify these findings are currently ongoing.

Keywords

Angiotensin Converting Enzyme Atenolol Angiotensin Converting Enzyme Inhibitor Hydrochlorothiazide HCTZ 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Belz GG, Essig J, Wellstein A. Hemodynamic responses to angiotensin I in normal volunteers and the antagonism by the angiotensin-converting enzyme inhibitor cilazapril. Journal of Cardiovascular Pharmacology 9: 219–224, 1987PubMedCrossRefGoogle Scholar
  2. Dzau VJ. Autocrine-paracrine renin-angiotensin systems in cardiorenal regulation and the pharmacology of ACE inhibitors. In Sonneblick EH, Laragh JH, Lesch M (Eds) New frontiers in cardiovascular therapy: focus on angiotensin converting enzyme inhibition, pp. 13–28, Excerpta Medica, Princeton, 1989Google Scholar
  3. Dzau VJ. Vascular renin-angiotensin system in hypertension. New insights into the mechanism of action of angiotensin converting enzyme inhibitors. American Journal of Medicine 84 (Suppl. 4A): 4–8, 1988PubMedGoogle Scholar
  4. Fasanella d’Amore T, Bussien JP, Nussberger J, Waeber B, Turini GA, et al. Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. Journal of Cardiovascular Pharmacology 9: 26–31, 1987PubMedGoogle Scholar
  5. Francis RJ, Brown AN, Kler L, Fasanella d’Amore T, Nussberger J, et al. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. Journal of Cardiovascular Pharmacology 9: 32–38, 1987PubMedGoogle Scholar
  6. Goldszer RC, Rodriguez R, Soloman HS. Efficacy and safety of cilazapril, a new angiotensin-converting enzyme inhibitor. American Journal of Hypertension 1: 300S–302S, 1988PubMedGoogle Scholar
  7. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: the 1988 report. Archives of Internal Medicine 148: 1023–1038, 1988CrossRefGoogle Scholar
  8. Laragh JH. The renin system and the impact of ACE inhibition for understanding, diagnosis, and treatment of hypertension. In Sonnenblick EH, Laragh JH, Lesch M (Eds) New frontiers in cardiovascular therapy: focus on angiotensin converting enzyme inhibition, pp. 83–116, Excerpta Medica, Princeton, 1989Google Scholar
  9. Nussberger J, Fasanella d’Amore T, Porchet M, Waeber B, Brunner DB, et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. Journal of Cardiovascular Pharmacology 9: 39–44, 1987PubMedGoogle Scholar
  10. Powell JS, Clozel JP, Müller RKM, Kuhn H, Hefti F, et al. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science 245: 186–188, 1989PubMedCrossRefGoogle Scholar
  11. Sanchez RA, Traballi CA, Barclay CA, Gilbert HB, Muscará M, et al. Antihypertensive, enzymatic, and hormonal activity of cilazapril, a new angiotensin-converting enzyme inhibitor in patients with mild to moderate essential hypertension. Journal of Cardiovascular Pharmacology 11: 230–234, 1988PubMedGoogle Scholar
  12. Schoenberger JA. Emerging benefits of angiotensin converting enzyme inhibitors versus other antihypertensive agents. American Journal of Medicine 84 (Suppl. 4A): 30–35, 1988PubMedGoogle Scholar
  13. Sealey JE. A separate prorenin-angiotensin system in reproductive and renal tissues? Evidence for renin gene expression in extrarenal vascular tissues is unconvincing. In Sonnenblick EH, Laragh JH, Lesch M (Eds) New frontiers in cardiovascular therapy: focus on angiotensin converting enzyme inhibition, pp. 29–46, Excerpta Medica, Princeton, 1989Google Scholar
  14. Tigerstedt R, Bergman PG. Niere und Kreislauf. Scandinavian Archives of Physiology 8: 223–271, 1898CrossRefGoogle Scholar
  15. Wellstein A, Essig J, Belz GG. Inhibition of angiotensin-I response by cilazapril and its time course in normal volunteers. Clinical Pharmacology and Therapeutics 41: 639–644, 1987PubMedCrossRefGoogle Scholar
  16. White WB, McCabe EJ, Hager WD, Schulman P. The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise, and ambulatory blood pressure. Clinical Pharmacology and Therapeutics 44: 173–178, 1988PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Thomas Szucs
    • 1
  1. 1.F. Hoffmann-La Roche LtdBaselSwitzerland

Personalised recommendations